TSMHT
IONS icon

Thurston Springer Miller Herd & Titak’s Ionis Pharmaceuticals IONS Stock Holding History

Thurston Springer Miller Herd & Titak’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-20
Closed -$801 – 1364
2024
Q3 		$801 Hold
20
– – ﹤0.01% 1440
2024
Q2 		$953 Buy
+20
New +$820 ﹤0.01% 1391

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
TBC
Tweedy, Browne Co Stamford, Connecticut $1.26B AUM 33.88% 1-Year Est. Return

Thurston Springer Miller Herd & Titak's IONS Position: Q4 2024 in Review

Thurston Springer Miller Herd & Titak sold out of Ionis Pharmaceuticals (IONS) in Q4 2024, closing a stake of 20 shares — an estimated $801 sold.

Thurston Springer Miller Herd & Titak first reported a position in IONS in Q2 2024 and held it in 2 quarters. The position peaked at $953 in Q2 2024. 354 funds tracked by Wall St. Rank hold IONS as of Q4 2024.

  • Thurston Springer Miller Herd & Titak reported no remaining Ionis Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Thurston Springer Miller Herd & Titak sold 20 Ionis Pharmaceuticals shares in Q4 2024, an estimated $801.
  • Thurston Springer Miller Herd & Titak first reported a position in Ionis Pharmaceuticals in Q2 2024 and held it in 2 quarters.
  • Thurston Springer Miller Herd & Titak's Ionis Pharmaceuticals position peaked at $953 in Q2 2024.
  • 354 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2024.

Based on Thurston Springer Miller Herd & Titak's 13F filing for Q4 2024, filed 14 Jan 2025.